OakChart

MetaVia Inc

MTVAHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.44-0.05 (-3.36%)
2026-11-12 05:02 CET
Market cap
9.49 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-14.45 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-4.04
P/E
-
Compare

Price

MTVA against its 20, 50 and 200-day averages
2050200miss
2.004.006.0042.6M85.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MTVAclose 1.4420-day 1.3050-day 1.48200-day 1.611.4452w low

89.3% under the 52-week high of 13.42 on 8 Dec 2025. 52-week low 0.97 on 12 May 2026. Last 15 sessions, 74.8% high to low

Volume 1.12× normal · the line is the 50-bar volume average

Profile

MTVA
52-week range, 4% of the way up
0.9713.42

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing novel pharmaceuticals to treat cardiometabolic diseases. It is developing DA-1726 for the treatment of various cardiometabolic conditions, with potential in both Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), and is advancing vanoglipel (DA-1241) in combination with resmetirom for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

Employees8
IPOAug 05, 2016
Beta1.18
ATR, 14d0.18
Rel volume1.12
Short float1.18%
Insider own28.08%
Inst own4.39%

Snapshot

6 groups

Valuation

Index-
Market Cap9.49M
Enterprise Value-2.96M
Income-14.45M
Sales0.00M
Book/sh1.04
Cash/sh1.92
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees8
IPOAug 05, 2016

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.39
P/C0.75
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio2.73
Current Ratio2.06
Debt/Eq0.03
LT Debt/Eq0.01
Option/ShortNo / Yes

Earnings

EPS (ttm)-4.04
EPS next Y-2.37
EPS next Q-0.73
EPS this Y65.76%
EPS next Y5.83%
EPS next 5Y39.14%
EPS past 3/5Y75.13% 72.69%
Sales past 3/5Y- -
EPS Y/Y TTM79.26%
Sales Y/Y TTM-
EPS Q/Q68.82%
Sales Q/Q-
EarningsAug 06 AMC
EPS/Sales Surpr.-9.76% -

Ownership

Insider Own28.08%
Insider Trans0.00%
Inst Own4.39%
Inst Trans3.64%
ROA-91.06%
ROE-175.68%
ROIC-208.61%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2011.18%
SMA50-2.63%
SMA200-10.80%
Trades-

Technical

Shs Outstand6.58M
Shs Float4.74M
Short Float1.18%
Short Ratio0.49
Short Interest0.06M
52W High13.42 -89.27%
52W Low0.97 49.05%
Volatility26.40% 13.68%
ATR (14)0.18
RSI (14)52.98
Beta1.18
Rel Volume1.12
Avg Volume115.46K
Volume129,442

Performance

Perf Week7.46%
Perf Month0.70%
Perf Quarter-1.37%
Perf Half Y20.00%
Perf YTD-82.90%
Perf Year-82.93%
Perf 3Y-96.20%
Perf 5Y-99.97%
Perf 10Y-100.00%
Recom1.00
Target Price17.67
Prev Close1.49
Price1.44
Change %-3.36%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Sep 04, 2025ResumedHH.C. WainwrightBuy$12+733.3%
Dec 30, 2024InitiatedHH.C. WainwrightBuy$12+733.3%

Peers

Mkt cap
TickerCompanyMkt cap
ALTAltimmune Inc375.41M
VKTXViking Therapeutics Inc3.63B
KLRAKailera Therapeutics Inc1.87B
GUTSFractyl Health Inc11.68M
GPCRStructure Therapeutics Inc ADR1.49B
SGMTSagimet Biosciences Inc802.60M
BMEABiomea Fusion Inc44.28M
IVAInventiva ADR958.79M
LEXXLexaria Bioscience Corp9.78M
MBXMBX Biosciences Inc2.87B

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 120
  • MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek 2026 (PR Newswire) +12.59%
  • MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data (PR Newswire) -18.66%
  • MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026 (PR Newswire)
  • MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer (PR Newswire)
  • MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction (PR Newswire)
  • MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
  • MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity (PR Newswire) +10.90%
  • MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum (PR Newswire)
  • MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential (PR Newswire) -13.62%
  • MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference (PR Newswire) -8.58%
  • MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH (PR Newswire) +12.46%
  • MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH (PR Newswire) +53.72%
  • MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions (PR Newswire)
  • MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire) -6.72%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-06-0.900-0.820-0.9000.000.003
2026Q12026-05-14-0.790-0.743-0.7870.000.003
2025Q42026-03-261.010-1.820-0.8360.000.003
2025Q32025-11-06-1.540-2.750-1.5210.000.004
2025Q22025-08-07-2.860-2.456-2.8750.000.003
2025Q12025-05-14-3.960-4.290-3.9340.000.003
2024Q42025-03-201.760-7.453-6.5880.000.004
2024Q32024-11-07-6.050-8.030-6.0870.000.002
2024Q12024-05-09---1.320---
2023Q32023-11-13---0.090---
2023Q22023-08-09---0.020---
2021Q32021-11-15---0.160---
2021Q22021-08-16---0.180---
2021Q12021-05-17---0.150---
2026Q3---0.733--0.003
2026Q4---0.753--0.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-27.060-24.750-27.0490.000.00
2024FY-39.160-43.698-39.1270.000.00
2025FY-7.350-8.887-7.3500.000.00
2026FY--2.517--0.00
2027FY--2.370--0.00
2028FY--1.657--0.00
2029FY--1.510---
2030FY--1.395---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-072000.000.000.00
2026Q3S2026-08-062000.000.000.00
2026Q3S2026-05-152000.000.000.00
2026Q3S2026-03-312000.000.000.00
2026Q3S2026-03-261000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00
2026Q3S2025-11-041000.000.000.00
2026Q3S2025-11-031000.000.000.00

Estimate history

EPS, annual-213180.001-9643.26-10769.854-4831.253-1743.43-477.574-27.049-39.127-7.346-4.0404
Period201720182019202020212022202320242025TTM
EPS, quarterly-20.369-6.087-6.588-3.934-2.875-1.521-0.836-0.787-0.896
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual00.0020.0060.0070.010.2890.4460.7852.3086.576
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.7470.7830.7850.7872.1992.2012.3085.1646.576
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.020.020.010.030.070.070.020.00
Gross Profit0.00-0.02-0.02-0.01-0.03-0.07-0.07-0.020.00
Selling, General and Administrative Excl. Other14.9213.6928.7915.8811.3915.2312.318.016.67
Research and Development7.736.8021.539.152.756.474.465.325.07
Other Operating Expense-0.000.000.000.000.000.000.000.00
Operating Income-14.93-13.71-28.81-15.89-11.42-15.30-12.38-8.03-6.67
Interest Expense-0.000.000.002.190.000.000.130.04
Unusual Expense-0.09-0.23-0.30-2.960.280.0017.3413.278.81
Net Income Before Taxes-14.45-12.97-27.59-12.47-13.97-15.28-29.68-21.31-15.53
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-14.45-12.97-27.59-12.47-13.97-15.28-29.68-21.31-15.53
Net Income From Continuing Operations-14.45-12.97-27.59-12.47-13.97-15.28-29.68-21.31-15.53
Net Income-14.45-12.97-27.59-12.47-13.97-15.28-29.68-21.31-15.53
EPS (Recurring)-2.45-7.44-39.42-31.54-470.99-1,743.44-2,855.43-6,077.50-5,811.46
EPS (Basic, Before Extraordinaries)-4.04-7.35-39.13-27.05-477.57-1,743.43-4,831.25-10,769.85-9,643.26
EPS (Diluted)-4.04-7.35-39.13-27.05-477.57-1,743.43-4,831.25-10,769.85-9,643.26
EBITDA--13.69-28.79-15.88-11.39-15.23-12.31-8.01-6.67
Non-Operating Income (Expense)0.390.510.920.46-0.080.010.040.11-0.00
Other After Tax Adjustments-0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.410.540.180.850.660.700.124.13
Shares Outstanding6.582.310.790.450.290.010.010.010.00
Market Capitalization9.499.4917.5317.760.6432.53103.27136.4411.55

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.010.010.010.010.000.010.01
Gross Profit0.00-0.01-0.01-0.01-0.01-0.00-0.01-0.01
Selling, General and Administrative Excl. Other5.384.022.043.474.303.885.586.25
Research and Development3.482.100.241.912.322.334.054.52
Other Operating Expense-0.000.000.000.000.000.000.00
Operating Income-5.38-4.03-2.05-3.48-4.30-3.89-5.58-6.26
Interest Expense-0.000.000.000.000.000.000.00
Unusual Expense0.00-0.12-0.030.05-0.16-0.09-0.20-0.30
Net Income Before Taxes-5.32-3.82-1.93-3.38-4.00-3.67-5.17-5.65
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-5.32-3.82-1.93-3.38-4.00-3.67-5.17-5.65
Net Income From Continuing Operations-5.32-3.82-1.93-3.38-4.00-3.67-5.17-5.65
Net Income-5.32-3.82-1.93-3.38-4.00-3.67-5.17-5.65
EPS (Recurring)-0.90-0.80-0.85-1.50-2.96-4.00-6.77-6.31
EPS (Basic, Before Extraordinaries)-0.90-0.79-0.84-1.52-2.87-3.93-6.59-6.09
EPS (Diluted)-0.90-0.79-0.84-1.52-2.87-3.93-6.59-6.09
EBITDA--4.02-2.04-3.47-4.30-3.88-5.58-6.25
Non-Operating Income (Expense)0.070.090.090.150.150.130.210.31
Other After Tax Adjustments-0.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.130.070.100.110.130.160.14
Shares Outstanding6.585.162.312.202.200.790.790.78
Market Capitalization9.496.1119.3722.7715.5613.3317.5327.29

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments10.2816.0222.4333.3616.3910.0913.922.8518.47
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.600.060.080.170.200.590.200.960.52
Total Current Assets10.8816.0722.5133.5316.5810.6814.123.8118.99
Net Property, Plant & Equipment0.230.170.250.000.210.280.350.010.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets---0.000.000.000.000.000.00
Deferred Tax Assets58.00--------
Other Assets0.020.020.020.000.000.000.000.000.03
Total Assets69.1216.2622.7833.5316.8010.9714.473.8219.02
Short Term Debt Incl. Current Port. of LT Debt0.070.080.070.000.030.020.020.001.35
Accounts Payable1.063.880.820.710.832.580.640.174.03
Other Current Liabilities4.524.315.0711.081.301.101.420.051.01
Total Current Liabilities5.658.275.9611.782.163.692.080.226.39
Long Term Debt0.140.060.140.000.040.070.090.028.68
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities58.00--------
Other Liabilities0.000.000.000.000.000.000.000.120.00
Total Liabilities63.798.336.1011.782.203.772.180.3615.08
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.0016.750.00
Common Equity5.337.9316.6821.7514.607.2012.29-13.293.94
Total Shareholders Equity5.337.9316.6821.7514.607.2012.293.463.94
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity5.337.9316.6821.7514.607.2012.293.463.94
Total Liabilities & Stockholders Equity69.1216.2622.7833.5316.8010.9714.473.8219.02
Book Value Per Share2.3110.1037.4175.251,445.37966.692,081.16-6,788.5324,462.05
Tangible Book Value Per Share2.3110.1037.4175.251,445.37966.692,081.16-6,788.5324,462.05
Full-Time Employees898611712918
Price to Book Ratio1.392.210.820.112.2314.3411.101.498.49
Return on Assets-30.39-141.35-44.29-55.50-110.09-233.35-124.77-136.00-152.68
Return on Equity-195.61-224.18-64.89-76.85-140.22-304.47-212.42-419.65-271.97
Return on Invested Capital-236.95-345.37-74.13-64.22-104.38-408.06-172.07-445.85-264.69
Quick Ratio1.931.943.782.857.692.896.7817.392.97
Current Ratio1.931.943.782.857.692.896.7817.392.97

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income--12.97-27.59-12.47-13.97-15.28-29.68-21.31-15.53
Depreciation-0.020.020.010.030.070.070.020.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00
Other Funds (Non Cash)-0.180.24-2.733.400.6618.0413.511.86
Funds from Operations--12.77-27.33-15.20-10.54-14.55-11.57-7.78-13.67
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital--2.932.624.40-1.17-0.580.810.74-0.78
Cash from Operating Activities--15.70-24.71-10.80-11.71-15.13-10.76-7.04-14.45
Capital Expenditures--0.00-0.01-0.050.00-0.00-0.00-0.21-0.00
Net Assets From Acquisitions-0.000.000.000.000.000.181.520.00
Sale of Fixed Assets and Businesses-0.000.000.000.010.000.000.000.00
Purchase or Sale of Investments-0.000.000.000.000.000.000.000.00
Purchase of Investments-0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments-0.000.000.000.000.000.000.000.00
Other Uses-0.000.000.000.00-0.58-0.11-7.370.00
Other Sources-0.000.000.000.000.000.000.000.00
Cash from Investing Activities--0.00-0.01-0.050.01-0.590.07-6.06-0.00
Cash Dividends Paid-0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Change in Capital Stock-9.9818.35-0.0828.6822.036.8624.1716.75
Repurchase of Common Pref Stock-0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-9.9818.35-0.0828.6822.036.8624.1716.75
Proceedsfrom Stock Options-9.9718.35-0.0828.6821.916.8024.1716.75
Issuance or Reduction of Debt, Net-0.000.000.000.000.000.000.000.50
Change in Long Term Debt-0.000.000.000.000.000.000.000.50
Issuance of Long Term Debt-0.000.000.000.000.000.000.000.50
Reduction of Long Term Debt-0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow--0.01-0.050.000.000.000.000.000.00
Other Financing Activities Uses--0.01-0.050.000.000.000.000.000.00
Cash from Financing Activities-9.9618.30-0.0828.6822.036.8624.1717.25
Exchange Rate Effect----0.00-0.010.000.010.00
Net Change in Cash--5.74-6.42-10.9316.986.30-3.8311.082.79
Free Cash Flow--15.70-24.72-10.85-11.71-15.14-10.77-7.25-14.45

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments12.6313.7310.2814.2817.5911.19
Short Term Receivables-0.000.000.000.000.00
Inventories-0.000.000.000.000.00
Other Current Assets0.430.430.600.290.730.77
Total Current Assets13.0714.1610.8814.5718.3211.96
Net Property, Plant & Equipment0.180.200.230.100.120.14
Total Investments and Advances-0.000.000.000.000.00
Deferred Tax Assets--58.00---
Other Assets0.020.020.020.100.020.02
Total Assets13.2714.3969.1214.7718.4612.13
Short Term Debt Incl. Current Port. of LT Debt0.070.070.070.080.080.08
Accounts Payable0.921.011.062.602.883.05
Other Current Liabilities5.354.114.525.765.864.58
Total Current Liabilities6.355.195.658.438.827.71
Long Term Debt0.100.120.140.000.010.04
Provision for Risks Charges-0.000.000.000.000.00
Deferred Tax Liabilities--58.00---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities6.455.3263.798.438.847.75
Non-Equity Reserves-0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity6.829.075.336.339.624.38
Total Shareholders Equity6.829.075.336.339.624.38
Accumulated Minority Interest-0.000.000.000.000.00
Total Equity6.829.075.336.339.624.38
Total Liabilities & Stockholders Equity13.2714.3969.1214.7718.4612.13
Book Value Per Share1.041.762.312.884.385.57
Tangible Book Value Per Share1.041.762.312.884.385.57
Full-Time Employees--8---
Price to Book Ratio1.390.522.933.601.623.04
Return on Assets-91.06-99.00-30.39-87.87-78.34-168.46
Return on Equity-175.68-195.12-195.61-168.18-129.46-339.64
Return on Invested Capital-76.77-41.57-35.25-53.34-41.45-83.11
Quick Ratio-2.731.931.732.081.55
Current Ratio2.062.731.931.732.081.55

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income--3.82-1.93-3.38-4.00-3.67
Depreciation-0.010.010.010.010.00
Other Funds (Non Cash)--0.020.040.15-0.050.04
Funds from Operations--3.83-1.89-3.22-4.04-3.62
Extraordinary Item-0.000.000.000.000.00
Changes in Working Capital--0.42-2.970.270.97-1.19
Cash from Operating Activities--4.26-4.86-2.96-3.07-4.82
Capital Expenditures-0.000.000.00-0.000.00
Net Assets From Acquisitions-0.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.000.000.000.00
Purchase or Sale of Investments-0.000.000.000.000.00
Purchase of Investments-0.000.000.000.000.00
Sale Or Maturity of Investments-0.000.000.000.000.00
Other Uses-0.000.000.000.000.00
Other Sources-0.000.000.000.000.00
Cash from Investing Activities-0.000.000.00-0.000.00
Cash Dividends Paid-0.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Change in Capital Stock-7.710.86-0.369.470.00
Repurchase of Common Pref Stock-0.000.000.000.000.00
Sale of Common Pref Stock-7.710.86-0.369.470.00
Proceedsfrom Stock Options-7.710.86-0.369.470.00
Issuance or Reduction of Debt, Net-0.000.000.000.000.00
Change in Long Term Debt-0.000.000.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.00
Net Financing Active Other Cash Flow-0.000.000.000.00-0.01
Other Financing Activities Uses-0.000.000.000.00-0.01
Cash from Financing Activities-7.710.86-0.369.47-0.01
Net Change in Cash-3.45-4.00-3.316.40-4.83
Free Cash Flow--4.26-4.86-2.96-3.07-4.82

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.18%0.1M4.7M78.54K
2026-10-152.08%0.1M4.7M83.25K
2026-09-302.45%0.1M4.8M236.31K
2026-09-153.83%0.2M4.8M262.69K
2026-08-314.40%0.2M4.8M597.81K
2026-08-144.91%0.2M4.3M3.83M
2026-07-314.76%0.2M3.4M3.84M
2026-07-1510.22%0.3M3.4M3.91M
2026-06-303.68%0.1M3.4M3.71M
2026-06-1512.31%0.4M3.4M3.65M
2026-05-2912.16%0.4M3.4M3.37M
2026-05-152.07%0.1M3.3M148.68K
2026-04-302.46%0.1M3.3M209.53K
2026-04-152.16%0.1M3.0M242.11K
2026-03-311.90%0.1M3.0M257.32K
2026-03-132.38%0.0M1.9M226.07K
2026-02-275.29%0.1M1.9M280.10K
2026-02-132.89%0.1M1.9M261.30K
2026-01-306.71%0.1M0.9M278.80K
2026-01-1517.74%0.2M0.9M222.08K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-05SEC
2026-10-288-KCurrent report2026-10-28SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-133Initial statement of beneficial ownership of securities2026-10-12SEC
2026-10-138-KCurrent report2026-10-13SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-098-KCurrent report2026-07-09SEC
2026-07-028-KCurrent report2026-07-02SEC
2026-07-02424B5SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-08S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-088-KCurrent report2026-06-08SEC
2026-06-088-KCurrent report2026-06-08SEC
2026-05-278-KCurrent report2026-05-27SEC
2026-05-188-KCurrent report2026-05-18SEC
2026-05-15SCHEDULE 13GSEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-118-KCurrent report2026-05-11SEC
2026-04-27ARSAnnual report to security holders. 2025-12-31SEC
2026-04-27DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-08SEC
2026-04-15PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-08SEC
2026-04-108-KCurrent report2026-04-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
JANE STREET GROUP, LLC2.39%
CITADEL ADVISORS LLC1.19%
Virtu Financial LLC0.58%
GEODE CAPITAL MANAGEMENT, LLC0.51%
Scientech Research LLC0.23%
VANGUARD CAPITAL MANAGEMENT LLC0.17%
Aries Wealth Management0.15%
VANGUARD FIDUCIARY TRUST CO0.13%
Tower Research Capital LLC0.04%
FMR LLC0.01%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.31%
VANGUARD EXTENDED MARKET INDEX FUND0.04%
Fidelity Total Market Index Fund0.01%
Fidelity Nasdaq Composite Index Fund0.01%
Fidelity Series Total Market Index Fund0.00%

OakChart. MTVA. Cached 15 minutes.

Some panels did not load: insider.